Filters: Author is Freedberg, Kenneth A [Clear All Filters]
"Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines." Archives of internal medicine 162, no. 8 (2002): 921-8. Abstract
"The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality." Journal of acquired immune deficiency syndromes (1999) 30, no. 4 (2002): 421-8. Abstract
"Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy." Antiviral therapy 7, no. 4 (2002): 257-66. Abstract
"State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards." Medical care 40, no. 5 (2002): 429-41. Abstract
"AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 35, no. 5 (2002): 606-10. Abstract
"Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy." Journal of acquired immune deficiency syndromes (1999) 31, no. 1 (2002): 27-37. Abstract
"Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection." The American journal of medicine 115, no. 8 (2003): 632-41. Abstract
"A therapeutic HIV vaccine: how good is good enough?" Vaccine 22, no. 29-30 (2004): 4044-53. Abstract
"Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients." Antiviral therapy 10, no. 1 (2005): 41-52. Abstract
"Expanded screening for HIV in the United States--an analysis of cost-effectiveness." The New England journal of medicine 352, no. 6 (2005): 586-95. Abstract
"Routine human immunodeficiency virus testing: an economic evaluation of current guidelines." The American journal of medicine 118, no. 3 (2005): 292-300. Abstract
"Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease." Journal of acquired immune deficiency syndromes (1999) 39, no. 1 (2005): 69-77. Abstract
"Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral." Medical decision making : an international journal of the Society for Medical Decision Making 25, no. 3 (2005): 321-9. Abstract
"Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients." Journal of acquired immune deficiency syndromes (1999) 43 Suppl 1 (2006): S113-8. Abstract
"Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs." Annals of internal medicine 145, no. 11 (2006): 797-806. Abstract
"The survival benefits of AIDS treatment in the United States." The Journal of infectious diseases 194, no. 1 (2006): 11-9. Abstract
"The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 44, no. 8 (2007): 1115-22. Abstract
"Cost-effectiveness of HIV testing and treatment in the United States." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 45 Suppl 4 (2007): S248-54. Abstract
"Scaling up antiretroviral therapy in South Africa: the impact of speed on survival." The Journal of infectious diseases 197, no. 9 (2008): 1324-32. Abstract
"When to start antiretroviral therapy in resource-limited settings." Annals of internal medicine 151, no. 3 (2009): 157-66. Abstract
"HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies." Journal of acquired immune deficiency syndromes (1999) 51, no. 3 (2009): 310-6. Abstract
"HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 48, no. 6 (2009): 806-15. Abstract
"Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 49, no. 10 (2009): 1570-8. Abstract
"Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal." PLoS medicine 6, no. 10 (2009): e1000173. Abstract
"Assessing the performance of a computer-based policy model of HIV and AIDS." PloS one 5, no. 9 (2010). Abstract
"Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India." PloS one 5, no. 9 (2010). Abstract
"Routine HIV screening in France: clinical impact and cost-effectiveness." PloS one 5, no. 10 (2010): e13132. Abstract
"Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis." PLoS medicine 7, no. 12 (2010): e1000382. Abstract
"Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 51, no. 4 (2010): 392-400. Abstract
"WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers." PloS one 6, no. 6 (2011): e20224. Abstract
"First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial." AIDS (London, England) 25, no. 4 (2011): 479-92. Abstract
"The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa." Journal of acquired immune deficiency syndromes (1999) 56, no. 1 (2011): 26-35. Abstract
"Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness." PloS one 8, no. 12 (2013): e84173. Abstract
"Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States." Annals of internal medicine 158, no. 2 (2013): 84-92. Abstract
"Cost-effectiveness of HIV treatment as prevention in serodiscordant couples." The New England journal of medicine 369, no. 18 (2013): 1715-25. Abstract
"HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy?" PloS one 9, no. 11 (2014): e113031. Abstract
"Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: A model-based analysis in Côte d'Ivoire." Journal of acquired immune deficiency syndromes (1999) (2014). Abstract
"Paltiel Letter to the Editor." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014).
"The survival benefits of antiretroviral therapy in South Africa." The Journal of infectious diseases 209, no. 4 (2014): 491-9. Abstract
"Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness." PloS one 9, no. 1 (2014): e85197. Abstract
"Misinterpretation of HIV preexposure prophylaxis findings." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 59, no. 1 (2014): 139-41.
"The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis." PLoS medicine 11, no. 9 (2014): e1001725. Abstract
"The lifetime medical cost savings from preventing HIV in the United States." Medical care 53, no. 4 (2015): 293-301. Abstract
"Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection." The Journal of infectious diseases (2015). Abstract
"The clinical role and cost-effectiveness of long-acting antiretroviral therapy." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). Abstract
"Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US." HIV clinical trials (2015): 1945577115Y0000000009. Abstract
